Disease relevance of PIGU

• (Nat Med 2004;10:374-81), that the oncogene CDC91L1 is not overexpressed at the mRNA level in urothelial cell carcinomas and cannot be used to predict the course of the disease [1].

High impact information on PIGU

• We identified CDC91L1, the gene encoding CDC91L1 (also called phosphatidylinositol glycan class U (PIG-U), a transamidase complex unit in the glycosylphosphatidylinositol (GPI) anchoring pathway), as the only gene whose expression was affected by the translocation [2].
• Our findings suggest that CDC91L1 is an oncogene in bladder cancer, and implicate the GPI anchoring system as a potential oncogenic pathway and therapeutic target in human cancers [2].
• CDC91L1 was amplified and overexpressed in about one-third of bladder cancer cell lines and primary tumors, as well as in oncogenic uroepithelial cells transformed with human papillomavirus (HPV) E7 [2].
• CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas [1].

Anatomical context of PIGU

• CDC91L1 (PIG-U) was recently discovered as a new oncogene in human bladder cancer and showed mRNA overexpression in 36% of primary bladder tumor tissues compared to normal urothelium [1].

Other interactions of PIGU

• CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer [2].

Analytical, diagnostic and therapeutic context of PIGU

• We further investigated CDC91L1 mRNA expression in 8 bladder cancer cell lines, 14 normal bladder tissues and 42 urothelial cell carcinomas by real-time quantitative PCR [1].

References